At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 963 enrolled
Drug / intervention
Fesoterodine +1 moredrug
Likely dose
Fesoterodine 4mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double Blind, Placebo Controlled, Parallel Group, Multicenter Trial To Evaluate The Efficacy And Safety Of A Fesoterodine Flexible Dose Regimen In Patients With Symptoms Of Overactive Bladder Including Nocturnal Urinary Urgency.
In Brief
A Phase 4 clinical trial evaluating Fesoterodine and Placebo for Overactive Bladder. Completed, enrolled 963 participants across 112 sites.
Detailed Summary
This study is designed to assess the efficacy of a flexible dose regimen of fesoterodine on micturition related nocturnal urgency episodes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOveractive Bladder
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJun 2009
Enrollment StartAug 2009
Primary CompletionSep 2011
TodayJul 2026
First PostedJun 3, 2009
Enrollment StartAug 1, 2009
Primary CompletionSep 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 17.1 years ago
Interventions
Fesoterodinedrug
Fesoterodine 4mg and 8 mg tablets taken daily.
Placebodrug
Placebo sham 4mg and 8 mg tables taken daily.